Neurodegenerative disease management最新文献_第4页

Donanemab for early symptomatic AD in the UK-indicated population: safety and efficacy in those who are non-carriers or heterozygous for APOE ε4. Donanemab在英国适应症人群中用于早期症状性AD: APOE ε4非携带者或杂合者的安全性和有效性

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-26 DOI: 10.1080/17582024.2026.2723524

Nuha Brookfield, Paula M Hauck, Erin G Doty, Jennifer A Zimmer, Fan Yang, Yun-Fei Chen, Paul Ardayfio, Rashna Khanna, Wenyu Ye, Antje Tockhorn-Heidenreich, Niraj Patel

{"title":"Donanemab for early symptomatic AD in the UK-indicated population: safety and efficacy in those who are non-carriers or heterozygous for APOE ε4.","authors":"Nuha Brookfield, Paula M Hauck, Erin G Doty, Jennifer A Zimmer, Fan Yang, Yun-Fei Chen, Paul Ardayfio, Rashna Khanna, Wenyu Ye, Antje Tockhorn-Heidenreich, Niraj Patel","doi":"10.1080/17582024.2026.2723524","DOIUrl":"https://doi.org/10.1080/17582024.2026.2723524","url":null,"abstract":"Background: Licensing of donanemab in the United Kingdom (UK) for the treatment of early symptomatic Alzheimer's disease is limited to adults who are Apolipoprotein E (APOE) ε4 non-carriers or heterozygotes.Aim: To assess safety and efficacy of donanemab in the UK-indicated population.Methods: Post-hoc analysis of APOE ε4 non-carriers or heterozygotes from a pooled TRAILBLAZER-ALZ and TRAILBLAZER-ALZ 2 population and the TRAILBLAZER-ALZ 2 population assessed safety and efficacy, respectively.Results: By 76 weeks, 13/825 (1.6%) and 170/816 (20.8%) participants in the placebo and donanemab arms experienced amyloid-related imaging abnormalities (ARIA)-edema/effusion, 96/825 (11.6%) and 218/816 (26.7%) participants experienced ARIA-microhemorrhages/superficial siderosis and 3/825 (0.4%) and 67/816 (8.2%) participants experienced infusion-related reactions, respectively. Donanemab significantly slowed disease progression versus placebo across multiple clinical scales, including a 40.3% (p < 0.0001) lower risk of progression to the next stage as measured by the Clinical Dementia Rating-Global score. Amyloid clearance occurred in 80.8% of donanemab-treated participants.Conclusions: In the UK-indicated population, excluding APOE ε4 homozygotes reduced, but did not eliminate, ARIA risk with donanemab. Treatment slowed disease progression and reduced brain amyloid plaque by 76 weeks. Therefore, donanemab treatment requires structured risk-benefit discussion and appropriate monitoring.Clinical trial registration: ClinicalTrials.gov, NCT03367403, https://clinicaltrials.gov/study/NCT03367403 (TRAILBLAZER-ALZ) and NCT04437511, https://clinicaltrials.gov/study/NCT04437511 (TRAILBLAZER-ALZ 2).","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-11"},"PeriodicalIF":2.8,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148819177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mapping public knowledge of Parkinson's disease in Portugal: a cross-sectional survey of knowledge, perceptions and attitudes. 绘制公众对葡萄牙帕金森病的认识：知识、观念和态度的横断面调查。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-25 DOI: 10.1080/17582024.2026.2723528

Inês Matos-Pina, Mariana Moura-Ramos, Cláudia Ferreira

{"title":"Mapping public knowledge of Parkinson's disease in Portugal: a cross-sectional survey of knowledge, perceptions and attitudes.","authors":"Inês Matos-Pina, Mariana Moura-Ramos, Cláudia Ferreira","doi":"10.1080/17582024.2026.2723528","DOIUrl":"https://doi.org/10.1080/17582024.2026.2723528","url":null,"abstract":"Aims: Research addressing knowledge about Parkinson's disease has grown remarkably. However, there is a scarcity of insight into the current state of knowledge in Portugal. Given the growing prevalence of Parkinson's disease, a comprehensive understanding of this scenario is a vital step toward improving health literacy. This study aims to explore public knowledge, perceptions and attitudes toward Parkinson's disease in the Portuguese population.Methods: A total of 784 individuals completed an online survey evaluating knowledge of Parkinson's disease, perceptions and attitudes. The survey was adapted from existing questionnaires on the topic for the purposes of this study and disseminated online.Results: Participants showed a good level of knowledge about Parkinson's disease. Although motor symptoms were greatly recognized, knowledge about non-motor symptomatology was considered insufficient. Women, younger ages (18-34 years) and those with superior education presented higher levels of knowledge. Misconceptions about certain aspects of the disease were identified, as well as some negative perceptions and attitudes toward Parkinson's disease.Conclusion: This study sheds light on a relevant gap in public knowledge about Parkinson's disease, which is closely related to its most unnoticed side-the wider spectrum of non-motor symptomatology. Implications for public health campaigns and specialized interventions are discussed.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-10"},"PeriodicalIF":2.8,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148813749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The hidden burden of depressive symptoms on functional autonomy in cognitive decline. 认知衰退中抑郁症状对功能自主的隐性负担。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-24 DOI: 10.1080/17582024.2026.2721356

Irene Cappadona, Maria Pagano, Anna Anselmo, Lilla Bonanno, Davide Cardile, Lorena Parisi, Francesco Di Prima, Rosaria De Luca, Fabrizio Sottile, Angela Marra, Antonella Alagna, Rocco Salvatore Calabrò, Angelo Quartarone, Francesco Corallo

{"title":"The hidden burden of depressive symptoms on functional autonomy in cognitive decline.","authors":"Irene Cappadona, Maria Pagano, Anna Anselmo, Lilla Bonanno, Davide Cardile, Lorena Parisi, Francesco Di Prima, Rosaria De Luca, Fabrizio Sottile, Angela Marra, Antonella Alagna, Rocco Salvatore Calabrò, Angelo Quartarone, Francesco Corallo","doi":"10.1080/17582024.2026.2721356","DOIUrl":"https://doi.org/10.1080/17582024.2026.2721356","url":null,"abstract":"Background: Cognitive decline involves a progressive loss of higher mental functions and may lead to impairment of independence in daily activities. Depressive symptoms represent a potential factor that can worsen functional decline.Objective: To evaluate the impact of depressive symptoms on basic and instrumental autonomy in patients with cognitive decline.Methods: A retrospective analysis was conducted on the medical records of 148 patients attending the Neuropsychology Clinic of the IRCCS Centro Neurolesi Bonino Pulejo. Patients were divided into two groups with and without depressive symptoms according to the Geriatric Depression Scale. The Milan Overall Dementia Assessment (MODA), Activities of Daily Living (ADL), and Instrumental Activities of Daily Living (IADL) were administered. Between-group comparisons were performed using the Mann-Whitney U test and permutation-based regression analysis, controlling for age, sex, and MODA. Correlations were assessed using Spearman's rho coefficient.Results: Patients with depressive symptoms showed lower ADL and IADL scores compared with those without depressive symptoms. These differences remained significant after adjustment for demographic and cognitive variables. The severity of depressive symptoms were strongly associated with reduced functional autonomy.Conclusions: The findings highlight the importance of early diagnosis and targeted interventions for depressive symptoms to improve patient management in everyday life. Clinical trial registration: www.clinicaltrials.gov identifier is NCT07287410.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-8"},"PeriodicalIF":2.8,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

RNA interference (RNA)-based therapeutics for treating neurodegenerative diseases. 以RNA干扰（RNA）为基础的治疗神经退行性疾病的方法。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-21 DOI: 10.1080/17582024.2026.2722300

Maryam Mahjoubin-Tehran, Amirhossein Sahebkar

引用次数: 0

Redefining Parkinson's disease: microglia and systemic immunity as gateways to early therapy. 重新定义帕金森病：小胶质细胞和全身免疫作为早期治疗的门户。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-20 DOI: 10.1080/17582024.2026.2721683

Alessandro Michelucci, Maria Tziortziou, Anne Grünewald

引用次数: 0

Incidence and clinical characteristics of amyotrophic lateral sclerosis during the post-COVID-19 Period: a population-based study from Isfahan, Iran. 后covid -19时期肌萎缩性侧索硬化症的发病率和临床特征：来自伊朗伊斯法罕的一项基于人群的研究

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-14 DOI: 10.1080/17582024.2026.2718409

Masoud Etemadifar, Mehri Salari, Mohammadamin Kashefi, Yalda Shams, Mohammadamin Heydari Sichani, Fatemeh Hojjatipour

{"title":"Incidence and clinical characteristics of amyotrophic lateral sclerosis during the post-COVID-19 Period: a population-based study from Isfahan, Iran.","authors":"Masoud Etemadifar, Mehri Salari, Mohammadamin Kashefi, Yalda Shams, Mohammadamin Heydari Sichani, Fatemeh Hojjatipour","doi":"10.1080/17582024.2026.2718409","DOIUrl":"https://doi.org/10.1080/17582024.2026.2718409","url":null,"abstract":"Aims: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder. Understanding the underlying causes would help further studies on the pathogenesis and treatments. Recent interest has emerged in evaluating whether the COVID-19 pandemic and vaccination have any influence on the epidemiological patterns of ALS.Materials & methods: To assess this association in Isfahan, Iran, during the post-COVID-19 era, we conducted this retrospective study. Newly diagnosed ALS cases were identified, and demographic data, environmental exposures, comorbidities, vaccination history, and other aspects were collected.Results: A total of 63 patients were diagnosed with definite ALS, yielding an incidence rate of 0.74 per 100,000 person-years (95% CI: 0.57-0.94). The mean age was 59.7 ± 11.6 years, and cases were predominantly male (73%). Of the 63 new ALS-diagnosed cases, 45% of patients reported probable prior COVID-19 infection, and 95.3% mentioned at least one dose of COVID-19 vaccination. Bulbar signs, including facial muscle weakness, tongue atrophy, and fasciculation, were present in 46% of cases, and emotional lability and cognitive decline were observed in 20.6%.Conclusion: We showed a probable relation between COVID-19 infection and the epidemiology of ALS in post-COVID era. However, our results and symptom alterations require further investigation.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-8"},"PeriodicalIF":2.8,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148760459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fecal microbiota transplantation in Parkinson's disease: a systematic review. 帕金森病的粪便微生物群移植：系统综述。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-10 DOI: 10.1080/17582024.2026.2715585

Negin Eissazade, Hesam Mosavari, Shayan Eghdami, Mohammad Rohani, Seyed-Mohammad Fereshtehnejad, Tara Khoeini

{"title":"Fecal microbiota transplantation in Parkinson's disease: a systematic review.","authors":"Negin Eissazade, Hesam Mosavari, Shayan Eghdami, Mohammad Rohani, Seyed-Mohammad Fereshtehnejad, Tara Khoeini","doi":"10.1080/17582024.2026.2715585","DOIUrl":"https://doi.org/10.1080/17582024.2026.2715585","url":null,"abstract":"Introduction: Current Parkinson's disease (PD) treatments offer limited, temporary relief. Fecal microbiota transplantation (FMT) is a potential therapy, but its safety and efficacy remain unclear.Methods: PubMed, Scopus, Cochrane Library, and Web of Science were searched on 20 July 2026. Eligible studies included adults with PD receiving FMT reporting motor and non-motor outcomes. Study quality was assessed using Joanna Briggs Institute checklists and Cochrane RoB 2. Due to heterogeneity, results were synthesized narratively.Results: Fourteen studies (nine trials, three case series, two case reports; 369 participants) were included. FMT protocols varied in stool preparation, delivery route, regimen, and follow-up (3-12 months). Four of six trials reported modest, short-term motor improvements. Non-motor benefits, mainly gastrointestinal function, sleep, and mood, were inconsistent. Microbiota analyses showed partial or temporary restoration toward healthy profiles. FMT was generally safe, with mainly mild, transient adverse events. Risk of bias varied: two high, four some concerns, one low.Conclusions: FMT appears safe and may provide short-term improvements in select motor and gastrointestinal outcomes in PD. Evidence is limited by small samples, heterogeneity, and methodological weaknesses. Well-designed, adequately powered RCTs with standardized protocols are needed to determine its therapeutic and disease-modifying potential.Registration: PROSPERO (CRD42024508462).","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-14"},"PeriodicalIF":2.8,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148707182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relationship between neck weakness in motor neurone disease and respiratory function: a retrospective study. 运动神经元疾病颈部无力与呼吸功能关系的回顾性研究

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-10 DOI: 10.1080/17582024.2026.2705867

Timothy P Sheehy, Trinh Sia, Prue E Morgan, Yan Zhao, Sally R Mathieson, Rosanne M Gibb, Anna A Smith, Christine A Wools

{"title":"Relationship between neck weakness in motor neurone disease and respiratory function: a retrospective study.","authors":"Timothy P Sheehy, Trinh Sia, Prue E Morgan, Yan Zhao, Sally R Mathieson, Rosanne M Gibb, Anna A Smith, Christine A Wools","doi":"10.1080/17582024.2026.2705867","DOIUrl":"https://doi.org/10.1080/17582024.2026.2705867","url":null,"abstract":"Aims: The primary aim was to explore the relationship between neck weakness in people with motor neurone disease (MND) and their respiratory function. The secondary aim was to identify whether neck weakness can be a prognostic factor.Methods: This was a retrospective observational cohort study. Data was collected from patient records on MND characteristics, neck weakness, respiratory function, and noninvasive ventilation (NIV) use. Multivariate modeling explored the effect of neck weakness on respiratory variables.Results: MND-related neck weakness was evident in 41% of 324 participants. Fifty-four percent used NIV and 17% became dependent on NIV during disease progression. The presence of neck weakness in MND was predictive of time to respiratory function decline, for respiratory outcomes (forced vital capacity (FVC) <65%, FVC <50% and NIV use) as well as having an effect on time to death. Median time from neck weakness onset to death was 8 months (IQR 10 months; range 0 to 60 months) with bulbar onset the quickest, median of 7 months (IQR 7 months, range 0 to 43 months).Conclusions: The presence of neck weakness is associated with a more rapid respiratory function decline in MND. In addition, neck weakness can be considered a prognostic factor in MND survival.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-8"},"PeriodicalIF":2.8,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148701908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Walking aids to improve gait in hereditary spastic paraplegia - effects and predictive parameters in a short-term sensor-based evaluation. 步行辅助改善遗传性痉挛性截瘫患者的步态-短期基于传感器评估的效果和预测参数。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-06 DOI: 10.1080/17582024.2026.2713717

Kathrin Kotter, Alzhraa Ibrahim, Veronika Koch, Verena Jakob, Juergen Winkler, Heiko Gassner, Martin Regensburger

{"title":"Walking aids to improve gait in hereditary spastic paraplegia - effects and predictive parameters in a short-term sensor-based evaluation.","authors":"Kathrin Kotter, Alzhraa Ibrahim, Veronika Koch, Verena Jakob, Juergen Winkler, Heiko Gassner, Martin Regensburger","doi":"10.1080/17582024.2026.2713717","DOIUrl":"https://doi.org/10.1080/17582024.2026.2713717","url":null,"abstract":"Introduction: Symptomatic management of hereditary spastic paraplegia (HSP) often involves assistive devices, yet neither the timing nor the choice of device is standardized, and their immediate impact on mobility in HSP remains poorly characterized. We aimed to quantify the immediate effects of classical walking aids in HSP, and to identify individualized responses.Methods: HSP patients and healthy controls performed a standardized 4 × 10 meters walking test under three conditions: unaided, with bilateral walking sticks, and with a four-wheel walker. Mobile gait parameters were recorded for each condition, and participants rated their perceived walking adaptations.Results: In the patient cohort (n = 46), assistive devices significantly improved step length, while other gait parameters were unchanged or worsened. Subgroup analyses indicated that patients with less clinical impairment, but greater fear of falling, older age, and higher body weight derived particular benefit from the use of walking aids. Subjective ratings were generally positive, with most patients assessing the devices as more helpful than baseline. Perceived improvements largely aligned with objective gait changes.Conclusions: Classical assistive devices may yield measurable, immediate benefits in gait performance in HSP reflecting patient perceptions. Future studies should investigate longer familiarization periods to evaluate sustained functional adaptations and optimize device recommendations.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-11"},"PeriodicalIF":2.8,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148679315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evidence-based physiotherapy recommendations for the management of motor aspects in amyotrophic lateral sclerosis. 肌萎缩性侧索硬化症运动方面的循证物理治疗建议。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-05 DOI: 10.1080/17582024.2026.2713034

Stephano Tomaz da Silva, Aline Alves de Souza, Luciana Protásio de Melo, Roberta de Oliveira Cacho, Ledycnarf Januário de Holanda, Leila Denise Neto Ortiz, Mário Emílio Teixeira Dourado Júnior, Igor Braga Farias, Filipe Gonçalves, Danilo Alves Pinto Nagem, Ricardo Alexsandro de Medeiros Valentim, Ana Raquel Rodrigues Lindquist, Tatiana Souza Ribeiro

{"title":"Evidence-based physiotherapy recommendations for the management of motor aspects in amyotrophic lateral sclerosis.","authors":"Stephano Tomaz da Silva, Aline Alves de Souza, Luciana Protásio de Melo, Roberta de Oliveira Cacho, Ledycnarf Januário de Holanda, Leila Denise Neto Ortiz, Mário Emílio Teixeira Dourado Júnior, Igor Braga Farias, Filipe Gonçalves, Danilo Alves Pinto Nagem, Ricardo Alexsandro de Medeiros Valentim, Ana Raquel Rodrigues Lindquist, Tatiana Souza Ribeiro","doi":"10.1080/17582024.2026.2713034","DOIUrl":"https://doi.org/10.1080/17582024.2026.2713034","url":null,"abstract":"Aim: To provide evidence-based recommendations for the physiotherapy management of Amyotrophic Lateral Sclerosis (ALS).Materials and methods: Evidence-based recommendations were developed by a multidisciplinary team, including PhDs and master's-level researchers, physicians, and experienced physiotherapists specializing in neurological rehabilitation.Results: After the selection process, 23 studies were included. Eighteen recommendations addressing motor aspects in ALS were formulated.Conclusions: Therapeutic exercise should be considered to improve or maintain ALSFRS-R scores in people with ALS. However, the effects of other interventions examined in this study remain uncertain with respect to motor aspects.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-11"},"PeriodicalIF":2.8,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148673800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0